期刊
CURRENT PHARMACEUTICAL DESIGN
卷 21, 期 36, 页码 5187-5197出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612821666150923095618
关键词
Active targeting; controlled drug delivery; osteosarcoma therapy; passive targeting; polymeric nanocarriers
资金
- National Natural Science Foundation of China [51303174, 51321062, 51233004, 51390484, 51273196, 51203153]
- Scientific Development Program of Jilin Province [20140520050JH]
Osteosarcoma (OS) is one of the most serious malignancies along with a high incidence in children and teenagers. Although the neoadjuvant chemotherapy of OS has made great progress and prolongs the five-year survival rates of patients to some extent, drugs are restrained from clinical application due to the unsatisfactory efficacy and severe side effects, especially for the systemic therapy through intravenous injection. The polymeric nanoparticles as anti-cancer drug nanocarriers make OS treatment more promising and effective. Specifically, various polymeric nanoparticles have been developed to overcome the difficulties in targeting delivery of drugs to OS tissue and/or cells through passive and/or active strategies. This review presents an overview on the development of polymeric nanoparticles for anti-cancer drug delivery in OS treatment, and briefly describes the challenge and opportunity for future development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据